
Determining the duration of immunity induced by booster doses of CoronaVac is crucial for informing recommendations for booster regimens and adjusting immunisation strategies. In two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, immunogenicity and safety of four immunisation regimens are assessed in adults aged 18 to 59 years and one immunisation regimen in adults aged 60 years and older, respectively. There are increases in the magnitude and duration of humoral response with homologous booster doses of CoronaVac given 8 months after a primary two-dose immunisation series, which could prolong protection and contribute to building our wall of population immunity.
Like
Save
Share